We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Metforminis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Metformin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1998–2022 with a typical study size of 753 participants.
Based on 7 studies · 1 meta-analysis · 3 RCTs · 806 total participants
Confidence
ModerateBy outcome
Metformin has an evidence score of 4/10 — emerging evidence based on 7 indexed studies, including 1 meta-analysis. A first-line type-2-diabetes drug (Glucophage) studied as a geroprotector and the basis of the TAME longevity trial. The human longevity case rests on diabetic-population epidemiology and one large meta-analysis; it is genuinely contested — including evidence it can blunt exercise adaptations. A prescription drug taken off-label, not a supplement. Representative study: PMID 28802803.
The commonly studied dose of Metformin is Off-label longevity use mirrors diabetes dosing (commonly 500–1500 mg/day of extended-release with meals) under a clinician. Not an approved longevity regimen, and unnecessary in well-controlled non-diabetics without a clear rationale.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Notable regimens that report including Metformin — documented, not endorsed.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Metformin (Glucophage)
A first-line type-2-diabetes drug (Glucophage) studied as a geroprotector and the basis of the TAME longevity trial. The human longevity case rests on diabetic-population epidemiology and one large meta-analysis; it is genuinely contested — including evidence it can blunt exercise adaptations. A prescription drug taken off-label, not a supplement.
Metformin is a safe, effective diabetes drug with plausible aging mechanisms and supportive epidemiology, but its longevity benefit in non-diabetics is unproven (TAME has not reported) and genuinely contested — including randomized evidence that it can blunt exercise adaptations — so the geroprotector case stays emerging.
Metformin is a biguanide and the most-prescribed type-2-diabetes drug in the world, with an excellent long-term safety record.
Its appeal as a geroprotector comes from biology and epidemiology: it activates AMPK, mildly inhibits mitochondrial complex I, reduces hepatic glucose output, lowers insulin/IGF-1 signaling, and improves insulin sensitivity — all pathways linked to aging.
Some observational studies found diabetics on metformin had lower all-cause mortality than non-diabetics, and a frequently-cited meta-analysis reported reduced all-cause mortality and age-related disease.
This generated the landmark TAME (Targeting Aging with Metformin) trial concept — a proposed RCT to test whether metformin delays multiple age-related diseases in non-diabetics.
The honest picture is that the longevity case is contested and unproven in non-diabetics: the epidemiology is confounded (metformin-treated diabetics differ from comparators), TAME has not reported, and several lines of evidence temper enthusiasm — most notably randomized data that metformin can blunt the cardiorespiratory and muscle-hypertrophy adaptations to exercise training, and signals that it may attenuate some benefits of exercise in older adults.
As a drug it is well tolerated; the main issues are GI upset, vitamin B12 depletion over time, and (rarely) lactic acidosis in renal impairment. Metformin is a prescription drug; using it off-label for longevity in a non-diabetic is reasonable to discuss with a clinician but not evidence-established.
The score reflects strong drug-level data and plausible mechanisms against genuinely contested, unproven human longevity benefit and a real exercise-interference trade-off.
Metformin activates AMP-activated protein kinase, the cellular energy sensor, shifting metabolism toward catabolism/maintenance — overlapping with caloric-restriction signaling.
Mild inhibition of mitochondrial complex I raises the AMP:ATP ratio and reduces hepatic gluconeogenesis, lowering blood glucose and insulin.
Improved insulin sensitivity and lower circulating insulin reduce IGF-1-axis signaling, a pathway whose reduction extends lifespan in models.
How Metformin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label longevity use mirrors diabetes dosing (commonly 500–1500 mg/day of extended-release with meals) under a clinician. Not an approved longevity regimen, and unnecessary in well-controlled non-diabetics without a clear rationale.
Loading: Titrate up gradually (e.g. start 500 mg/day with food) to limit GI side effects; no loading dose.
Take with food
| Form | Type |
|---|---|
| 💊Extended-release tablet | Recommended |
| 💊Immediate-release tablet | Alternative |
ER form is better tolerated; no advantage to grey-market sourcing of a cheap generic drug.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: With meals to limit GI upset; extended-release typically once daily with the evening meal.
Dose-response data unavailable. The current published research for Metformin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lowers blood glucose and HbA1c and improves insulin sensitivity — the established, proven effect.
Observational and meta-analytic data suggest lower all-cause mortality and age-related disease in diabetics — confounded, not proven causal.
Randomized data show metformin can attenuate cardiorespiratory-fitness and muscle gains from exercise training — a real trade-off for active users.
Diarrhea/nausea (often transient) and gradual vitamin B12 depletion with long-term use.
Weigh the exercise-blunting evidence — metformin may attenuate training adaptations.
Dose-reduce or avoid; contraindicated below eGFR 30.
Discuss with a clinician — benefit is unproven and not an approved use.
Hold around contrast imaging in renal impairment — lactic-acidosis risk.
Heavy alcohol raises lactic-acidosis risk.
Tip: Take with food; use extended-release; titrate slowly. Often transient.
Tip: Monitor B12 on long-term use; supplement if low.
Tip: Avoid in significant renal impairment; very rare with normal kidney function.
The best time to take Metformin is with meals. Take it with food. Taking with meals reduces GI upset; extended-release once daily improves tolerability.
Metformin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are GI upset (diarrhea, nausea), vitamin B12 depletion, lactic acidosis. Use caution if any of these apply to you: Severe renal impairment (eGFR < 30); Acute metabolic acidosis; Conditions predisposing to lactic acidosis (severe hypoxia, decompensated heart failure).
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.